- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 407/12
Total number of patents in this class: 1480
10-year publication summary
|
109
|
81
|
97
|
101
|
123
|
65
|
94
|
92
|
80
|
64
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4826 |
39 |
| Duk San Neolux Co., Ltd. | 668 |
37 |
| Merck Patent GmbH | 5752 |
28 |
| LT Materials Co., Ltd. | 414 |
28 |
| Takeda Pharmaceutical Company Limited | 2721 |
25 |
| Boehringer Ingelheim International GmbH | 4636 |
24 |
| LG Chem, Ltd. | 17706 |
20 |
| F. Hoffmann-La Roche AG | 7937 |
18 |
| Samsung Display Co., Ltd. | 36317 |
18 |
| Syngenta Participations AG | 1730 |
14 |
| Vertex Pharmaceuticals Incorporated | 1630 |
14 |
| Ono Pharmaceutical Co., Ltd. | 428 |
14 |
| BASF SE | 21098 |
13 |
| Idemitsu Kosan Co., Ltd. | 4223 |
13 |
| Abbvie Inc. | 1817 |
13 |
| Daiichi Sankyo Company, Limited | 1879 |
13 |
| Genentech, Inc. | 4016 |
12 |
| Janssen Pharmaceutica N.V. | 3358 |
12 |
| Celgene Corporation | 1403 |
11 |
| Crius Technology Group, Inc. | 22 |
11 |
| Other owners | 1103 |